TAILIEUCHUNG - Self-driving cars: The next revolution

KPMG LLP and the Center for Automotive Research (CAR) joined forces in developing this white paper to examine the forces of change, the current and emerging technologies, the path to bring these innovations to market, the likelihood that they will achieve wide adoption from consumers, and their potential impact on the automotive ecosystem. Our research included interviews with more than 25 thought leaders, automotive and high- tech executives, and government officials as well as analysis of industry trends. This white paper presents our findings, with an emphasis on the convergence of sensor-based and communication-based vehicle technologies and its implications | 7 Ă A message from Gary Silberg and Richard Wallace For 125 years the automotive industry has been a force for innovation and economic growth. Now in the early decades of the 21st century the pace of innovation is speeding up and the industry is on the brink of a new technological revolution selfdriving vehicles. The new technology could provide solutions to some of our most intractable social problems the high cost of traffic crashes and transportation infrastructure the millions of hours wasted in traffic jams and the wasted urban space given over to parking lots just to name a few. But if self-driving vehicles become a reality the implications would also be profoundly disruptive for almost every stakeholder in the automotive ecosystem. As one industry executive put it Everything from how we move goods to how we move ourselves around is ripe for change. KPMG LLP and the Center for Automotive Research CAR collaborated on this report interviewing leading technologists automotive industry leaders academicians and regulators to develop hypotheses on how self-driving vehicle technology could unfold and its potential impacts. It is clear from our research that any company remaining complacent in the face of such potentially disruptive change may find itself left behind irrelevant. For those who embrace innovation and opt to lead rather than follow a new frontier is opening in the realm of mobility services. We hope you will find our report illuminating and that we will have opportunities to discuss our findings with you in the near future. Gary Silberg Partner KpMg LLP National Sector Leader Automotive RichardWallace Director Transportation Systems Analysis Center for Automotive .

• Cơ khí - Chế tạo máy
• Metastatic Pancreatic Cancer
• Pancreatic Cancer
• Clinical Course
• Nutrition in Healthy Children
• Growth and Development
• Pediatric Cardiology
• BMC Cancer
• Enzyme gamma glutamyltransferase
• Serum gamma glutamyltransferase
• Overall survival
• Recurrent pancreatic ductal adenocarcinoma
• Recurrent pancreatic cancer
• Gemcitabine nab paclitaxel
• Combination chemotherapy
• Liver metastases
• Liver directed therapy
• Systemic chemotherapy
• Metastatic pancreatic ductal adenocarcinoma
• Nab paclitaxel
• Pancreatic adenocarcinoma
• Randomized phase III trial
• Progressive disease
• Subgroup analysis
• MPACT trial
• Subsequent therapy
• Weekly nab paclitaxel plus gemcitabine
• Phase II study
• H 1 parvovirus
• Oncolytic virotherapy
• Pancreatic ductal adenocarcinoma
• Clinical protocol
• Body mass index
• Prognostic factors
• Physical activity
• Skeletal muscle density
• Metastatic pancreatic adenocarcinoma
• Prognostic factor
• Journal of Biology
• CRISPR/dCas9 activation
• Pancreas cancer
• Pancreatic ductal adenocarcinoma (PDAC)
• Metastatic pancreatic cancer cells
• Real life
• First line chemotherapy
• Locally advanced
• Metastatic disease
• Locally advanced pancreatic adenocarcinoma
• Kaplan–Meier method
• Second line chemotherapy
• Venous thromboembolism
• Predictive value
• Khorana score
• Gemcitabine chemotherapy
• Therapeutics strategy
• Laboratory parameters
• Clinicopathological factors
• White blood cell
• Survival
• Endoscopic Management
• Palliative Therapy